Skip to main content

Stem cell transplant backed after relapsing MS drugs fail

By MS Buddy ·

Summarized from Nature reviews. Neurology, Jan 2025 · PubMed · DOI. AI-generated summary. Not medical advice.

Review · people with relapsing or progressive MS and an MS look-alike condition

Research by Paolo Muraro, Basil Sharrack and 27 colleagues at the University of Genoa, Imperial College and 9 other institutions in Italy, the United Kingdom, Sweden and 5 other countries.

When do experts recommend a stem cell transplant for MS?

Key Takeaway

Experts generally support stem cell transplants for aggressive relapsing MS after strong MS drugs have failed.

Two faceless figures look toward a cluster of cells beside a path blocked by plain shapes.
Credibility
Interest
Share:1 min read

What They Found

Experts generally accept stem cell transplant as an option for aggressive relapsing MS after strong MS drugs fail. They do not agree on exactly when it should come in the treatment sequence. Evidence is less clear for severe MS before drug treatment and for progressive MS. Evidence is also less clear for a condition often mistaken for MS. The experts gave care recommendations based on available evidence or, when evidence was lacking, their shared judgment.

Who Should Care and Why

This statement concerns people with relapsing or progressive MS and people with a condition often mistaken for MS. Its clearest guidance concerns aggressive relapsing MS after strong drugs have failed. It also discusses severe MS in people who have not yet started drug treatment. Experts considered care before and after a stem cell transplant, including rehabilitation and follow-up. They identified questions that still need research.

Important Considerations

You are reading expert guidance, not results from a new treatment trial. The abstract gives no participant count or new comparison of treatments. You cannot tell from this abstract whether a transplant works for progressive MS or the MS look-alike condition.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Nature reviews. Neurology by et al.. Reproduced from the PubMed record.

Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsing forms of multiple sclerosis (MS) that are refractory to disease-modifying therapy (DMT). AHSCT after failure of high-efficacy DMT in aggressive forms of relapsing-remitting MS is a generally accepted indication, yet the optimal placement of this approach in the treatment sequence is not universally agreed upon. Uncertainties also remain with respect to other indications, such as in rapidly evolving, severe, treatment-naive MS, progressive MS, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, treatment and monitoring protocols, rehabilitation and other supportive care before and after AHSCT need to be optimized. To address these issues, we convened a European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop in partnership with the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party, in which evidence and key questions were presented and discussed by experts in these diseases and in AHSCT. Based on the workshop output and subsequent written interactions, this Consensus Statement provides practical guidance and recommendations on the use of AHSCT in MS and NMOSD. Recommendations are based on the available evidence, or on consensus when evidence was insufficient. We summarize the key evidence, report the final recommendations, and identify areas for further research.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
Muted blue paths widen and join across soft gray layers on an off-white background.
MS treatment in Poland started sooner, reached more people

11/13/2026

From 2013 to 2024, more people with MS in Poland received treatment and started sooner. Stronger dru

Read More
Two parallel paths cross uneven ground; one has fewer steep rises than the other.
Ocrevus cut disability worsening in high-risk relapsing MS

1/1/2027

In treatment trials, Ocrevus lowered disability worsening risk for a high-risk group with relapsing

Read More
MS Study Finds Fewer Alzheimer’s Diagnoses With One Drug

11/3/2026

A large MS records study found fewer Alzheimer’s diagnoses among people given natalizumab. Learn wha

Read More
MS Infusion Timing: Why Longer Gaps May Need a Check

11/2/2026

A case report links longer gaps between MS infusions with low drug levels and antibodies. Learn what

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.